| In this subgroup (N=13), 3 partial responses (≥50% tumor shrinkage) and 7 cases with stable disease were observed, resulting in an overall disease control rate of 77%. Of note, 6 of 7 patients that were refractory to brentuximab vedotin had a stabilization of their disease, an indication that this patient population may also benefit from AFM13 treatment. Based on these data a phase 2 study is being prepared with an optimized dosing regimen designed to demonstrate the full therapeutic potential of AFM13 in relapsed/refractory HL patients.
In August 2013, Affimed signed an agreement with the Leukemia and Lymphoma Society (LLS) under which LLS committed to co-fund up to $4.4 million over two years for the phase 2a development of AFM13. In doing so, the LLS recognized the critical need for safer and more durable therapies for HL. The LLS is committed to advancing breakthrough therapies, particularly for patients with unmet medical needs. The LLS is the world’s largest voluntary health agency dedicated to blood cancer; its mission is: cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.